Microsoft Names Leader, Chief Scientist of AI Organization — Update
By Ben Glickman
Microsoft on Tuesday named Mustafa Suleyman, one of the founders of artificial-intelligence startup DeepMind, to lead its AI products and research.
The tech giant said that Suleyman would lead a new organization called Microsoft AI, which would oversee the Copilot AI assistant and other consumer AI products and research.
The new organization would also include Karén Simonyan as chief scientist. Simonyan is an AI researcher who was co-founder and chief scientist for startup Inflection.
Suleyman was also a founder of Inflection alongside Simonyan.
The two appointments and the creation of the AI organization was announced Tuesday in a communication to employees by Microsoft CEO Satya Nadella.
Microsoft said that several members of the team at Inflection would also join the company.
Chief Technology Officer and executive vice president of AI Kevin Scott will continue in his role and will be responsible for overall AI strategy, Nadella said.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
March 19, 2024 13:16 ET (17:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track